Teva presents data confirming target engagement o TEV-‘574 at ECCO meeting

Teva Pharmaceuticals announced positive safety, tolerability, and pharmacokinetic data for its anti-TL1A or TEV-‘574 asset, a potentially best-in-class human IgG1 monoclonal antibody that targets the tumor necrosis factor,TNF-like ligand 1A, TL1A, and is designed to offer both anti-inflammatory and anti-fibrotic effects.1-3 The data show the rapid and sustained suppression of free TL1A, confirming the target engagement of anti-TL1A , and show a well-tolerated safety profile in patients with asthma, which support continued clinical investigation for moderate-to-severe inflammatory bowel disease IBD; this includes ulcerative colitis UC and Crohn’s disease CD.1-3 These findings will be presented at the 19th Annual Congress of the European Crohn’s and Colitis Organisation ECCO, which takes place February 21-24, 2024, in Stockholm, Sweden. “These results from the first-in-human trials of anti-TL1A, TEV-‘574, are exciting because they show that it effectively engages with the TL1A target, supports its safety profile and is well-tolerated. This aligns with our extensive pre-clinical evidence and further supports ongoing clinical investigations of anti-TL1A in IBD, where TL1A plays a prominent role in amplification of immune response leading to burdensome inflammation and fibrosis in the gastrointestinal tract,” said Dr. Eric Hughes, Executive Vice President of Global R&D and Chief Medical Officer at Teva. “We are currently investigating the efficacy and safety of anti-TL1A in IBD through the RELIEVE UCCD Phase 2 trial, which features an innovative and efficient basket study design allowing the inclusion of patients with either type of IBD , ulcerative colitis and Crohn’s disease. These data reinforce the potential for anti-TL1A to become a novel treatment option for IBD and solidifies our ongoing commitment to provide innovative medicines to improve the lives of people living with IBD, as quickly as possible.”